accompanied by his wife, Rosemary (figure 4), flew off to spend a year with Fred Plum in New York. On his return, he became a consultant neurologist at the National Hospital and took up the study of human intercostal muscle spindles. It was this preparation that led him to MG. As Tom Sears, now Emeritus Professor of Neurophysiology, King's College London, recalled: 'My friend, Professor Ricardo Miledi, after distancing himself for many years from human based research, phoned to ask if I knew anyone carrying out intercostal muscle biopsies. I said "I do and it so happens he is by my side." They got together soon after and the rest is history.' JND and Ricardo collaborated for four years, but in 1977 JND established an independent MG group in Peter Thomas' Clinical Neurosciences Department at the Royal Free Hospital (RFH) (see Asbury et al. 2011) . This also broke the continuity of his working relationship with Tom but there was no doubt that his time with Tom was greatly valued. As described in detail below, the RFH MG group grew rapidly; the first experiments were performed on the requisitioned coffee table but by 1985, generously encouraged by Peter and his team, and largely supported by the award of two large Medical Research Council (MRC) Programme Grants (1979 Grants ( -1984 1984 -1999 , the core team was formed, research assistants, students and the first tranche of visiting clinical fellows taken on, and about two-thirds of the lab space in Peter's department devoted to myasthenia research.
University of Oxford, 1987 Oxford, -2007 In the mid-1980s JND was asked whether he would be interested in succeeding Brian Matthews as Professor of Clinical Neurology in Oxford. As Professor Sir David Weatherall (FRS 1977) recalled,
One might wonder why he should have wished to move at this stage, since by this time he had been appointed MRC Clinical Research Professor of Neurology and had obtained two MRC Programme Grants with more likely to follow. He had also gathered together a diverse and talented research team and the clinical environment at Queen Square, where he continued to see patients, was excellent. The question posed for Oxford, therefore, was how might he be tempted away from this excellent environment. The temptation was the Institute of Molecular Medicine (IMM).
In 1979, the MRC had established a Molecular Haematology Unit in Oxford directed by David Weatherall, reflecting the increasing role of molecular and cell biology for the investigation of inherited blood diseases. It was apparent that the techniques used would have wide implications across medicine, and there was a need to train young clinicians in these methods, and provide an ideal environment for clinically orientated basic scientists to work. David Weatherall attracted further MRC and other funding to create the IMM and wanted to include neuroscience in this multidisciplinary institute.
At first, John was quite reluctant to leave London but at a chance meeting at a research policy meeting at Leeds Castle, JND became convinced of the opportunity that a move to Oxford presented and was appointed Professor of Clinical Neurology in 1987. (Professor Sir David Weatherall) JND had a major impact on both medicine and the broader aspects of university life during his time as the Action Research Professor of Neurology in Oxford (1987 Oxford ( -1998 . While managing an increasingly active research group, and despite innumerable calls on his time from activities outside Oxford, he maintained and expanded the excellent clinical neurology services at the Radcliffe Infirmary. He recruited neurologist Michael Donaghy and neurophysiologist Kerry Mills to Oxford as Clinical Readers, and brought Margaret Esiri and the academic work of the Neuropathology Department into Neurology. He also appointed Peter Rothwell as Clinical Lecturer; subsequently Peter created the Stroke Prevention Unit, filling a gap left open by the departure of Charles Warlow to Edinburgh. Remarkably, in the mid-1990s, with Alan Cowey (FRS 1988) and George Radda (FRS 1980) , JND persuaded the MRC to create a functional imaging centre. They brought back Paul Matthews from London, Ontario, to direct it, and the Functional Magnetic Resonance Imaging of the Brain centre, FMRIB (now directed by Professor Heidi Johansen-Berg), has subsequently become a world player in clinical and basic imaging and its applications.
Overall, in the eleven years that he held the Chair of Clinical Neurology, he developed a remarkably active clinical academic department with a research base stretching from the bedside to imaging and immunology, and numbering over 60 scientists.
John was also remarkably unselfish about giving time to help major organisational developments and activities in the Medical Faculty. He was a very effective member of the Board of the Faculty of Clinical Medicine from 1990-1993 and chaired the Animal Care Committee at the same time. This was a period of rapid expansion of the Medical Faculty and John was a major influence in many directions, always giving a solid and balanced view of where the Faculty should be going. He also served the University as a Delegate of the University Press for five years, a rather terrifying body which meets regularly each term and has the last word on which books should be published by the Press. His breadth of interests and balanced approach were of particular value to this heterogeneous group of academics. During this time John also had many commitments outside Oxford including time-demanding work for the Department of Health, the Royal Society (elected FRS in 1991) , the Royal College of Physicians, and the British Association for the Advancement of Science [BAAS] . (Professor Sir David Weatherall) It was at a meeting of the BAAS in 1983 that he attracted considerable media interest when he proposed that Samson had both MG and autoimmune alopecia (hair loss, Delilah gets off the hook) and it was only following a spontaneous improvement in both diseases that his hair grew and he was able to pull down the temple. The media attention that followed this retrospective diagnosis did not meet with everyone's approval at the time.
Medical Research Council
The 1990s were a time of change and challenges in research funding. The former Chief Executive Officer of the MRC, Sir Dai Rees (FRS 1981) , writes:
John was a wise and constructive colleague who contributed much to help MRC through difficult times. We had to learn how to think in new ways about finances, about accountability not only for the science but for political correctness. The departures from MRC tradition threatened to dissolve the community into warring tribes-basic versus clinical, direct support versus indirect, each discipline against others, primary care and public health versus advanced diagnostics and treatment. The neuroscience community had seen great glory in the past, and would see more in the future, but the new challenge of sharing the glamour and thus the resources with brightly plumaged new cuckoos such as molecular biology and genetics, made some suspicious of the MRC Council's commitment. The proposed reforms of the Clinical Research Centre, then at Northwick Park, struggled under the baleful eye of the Prime Minister (Margaret Thatcher), particularly when she became persuaded that the reforms represented a threat to hospital access for her Finchley constituents. As Council Member, and particularly as Chair of the Neurosciences Board, John was in the eye of several storms. I had the impression that he found it rather fun, respecting and even admiring the enthusiasm and honest commitments of the impassioned. With his eminence and senior membership of key communities, and his cool head but personal warmth, John could put the case for the greater good with an authority and persuasiveness that outsiders to these groups could not. MRC could hardly be in such good shape now without the dedicated and imaginative efforts of John and the allies he gathered around him.
Editor of Brain and President of the Association of British Neurologists
As he began to plan for his 'retirement', John agreed to take over from Ian McDonald as editor of Brain, a journal that John had already served as secretary and treasurer (1977) (1978) (1979) (1980) (1981) and as chairman of the Guarantors and Board of Management (1994 Management ( -1999 . Brain had acquired a reputation for being fusty, and as the 'Queen Square house journal', but John had a knack for sniffing out work that was forward-looking and contemporary; and he introduced electronic processing and online publication well ahead of other journals in the field. (Professor Alastair Compston (FRS 2016)) Another change was to appoint a Deputy Editor to help, and John Rothwell (Institute of Neurology) proved to be an excellent choice.
When John took over Brain, like all new editors, he wanted to bring the journal up to date and make the journal one of the first to enter the internet age. He thought that this would broaden submissions, especially from outside the UK, and appeal to a younger audience. He wanted more emphasis on the new fields of genetics and molecular biology. So we began the process of transferring from a paper-based to an electronic journal. This was in the days when most internet connections outside the university were via telephone lines, so that keeping up with submissions when on holiday or even at meetings, could be a tedious business involving dropped connections and long pauses in transmission of papers. It was also not without its teething problems, since Brain was one of the first large journals to be taken on by the Manuscript Central system; although for a time this was an advantage as we had a reasonable influence on how they began to develop the site. The transition was remarkably smooth, authors and reviewers liked it and submissions began to increase dramatically. The impact factor began to rise, as less normative neuroimaging and more genetics and molecular biology papers were encouraged. It had become an unreasonable number of submissions for two editors to process, and was ripe for change when the new editor, Alastair Compston took over. (Professor John Rothwell) The Association of British Neurologists (ABN) provided another activity.
As a former secretary (1981) (1982) (1983) (1984) and medallist (1999), it was natural that the membership wanted John to serve as president (1999) (2000) . He felt that the Association had drifted away from its origins (in 1932) as a forum for discussing the best of British scientific neurology. As a first step, he established a Clinical Research Advisory Committee to foster the clinical sciences. (Professor Alastair Compston) Marriage and family life JND's first introduction to Rosemary Schmid in 1960 was not propitious. 'She thought him much too quiet whereas he remembered someone overconfident who talked far too much' (Rosemary Newsom-Davis). However, they met again at an opera party in 1963 and, with earlier prejudices forgotten, they married later that year. Rosemary worked as an educational psychologist; they settled in North London, and had three children, Amelia (b. 1970 ), Imogen (b. 1972 and Tom (b. 1973) . The family moved to Oxford in 1987 but, following his official retirement in 1998, he and Rosemary returned to London. Amelia now lives in Paris and works in media marketing, Imogen is a paediatric neuropsychologist, whilst Tom is an oncologist at the Westminster and Chelsea Hospital, part of the Imperial College School of Medicine. All three are married with children and Rosemary continues to live in West London.
Science and medicine were never far from JND's mind. However, when needed, he would distract himself from work through cooking (an interest he inherited from his mother), gardening and his seven grandchildren. He had a lifelong love of music, although he played no instrument himself, and regularly attended concerts and opera. Yet he was a reluctant tourist and on family holidays would usually be seen contemplating his most recent manuscript instead of admiring the relevant sights. (Dr Tom Newsom-Davis)
Research
Respiratory physiology (1965) (1966) (1967) (1968) (1969) (1970) (1971) (1972) (1973) (1974) (1975) and myasthenia at the National Hospital Tom Sears, JND's MD supervisor, friend and colleague, describes their work together:
Moran Campbell had carried out experiments testing the ability of human subjects to perceive increased resistive or elastic loading of the airways; and he had drawn on contemporary ideas of the 'length follow-up servo control of movement' to propose imaginatively that perception depended on 'length-tension' inappropriateness to account for the results. However, the servo theory at the time conceived a muscle spindle-dependent reflex mechanism automatically subserving motor control without conscious intervention. In fact the conscious response to loading of limb muscles at that time was assigned to joint receptors with afferent pathways to the brain in the posterior columns. The neurologist Richard Godwin-Austen had recently finished a study of intercostal joint mechanoreceptors in the cat, examining these receptors as a possible source of chest wall proprioception to account for sensibility of dyspnoea (breathlessness). Around that time I was examining electromyographically the response of the intercostal muscles to altered mechanical loading (Sears 1964) . I therefore suggested to John that he should investigate the perception of load in patients with impaired position sense or other criteria of posterior column dysfunction. On alternate weeks John and I would impale each other with wire EMG electrodes, inserted in the external or internal intercostal muscles, to examine their reflex responses to sudden changes in pressure which could either assist or oppose the voluntary sustained lung volume, or a steadily decreasing or increasing one; similarly, a solenoid valve was used to increase or decrease the mechanical load (airway resistance). The research was based on insights gained from intracellular recordings of the central respiratory drive and the monosynaptic reflexes of intercostal motoneurones. In this way we were able to provide a comprehensive account of the segmental reflex responses of these muscles, particularly in relation to the topographic distribution of activities across the chest wall as well as to the lung volume (% Vital Capacity) at which the perturbation was introduced (1, 3). Thus our conceptual framework centred on the muscle spindle, and John, who had access to human intercostal muscle biopsies, subsequently used the same experimental rig to examine the muscle spindles in these muscles, and provided the first account of their activation in his in vitro preparation (7).
From this experience John gained invaluable experience in electrophysiological measurements and subsequently became very interested in hiccup (4), describing a new method to measure conduction velocity of human phrenic nerve fibres which hitherto had depended on oesophageal electrodes (2). Surface electrodes placed over the insertion of the diaphragm in the lower ribs provided clean EMG signals in response to stimulation of the phrenic nerve in the neck, thus providing objective data where the assessment of paradoxical movement was equivocal.
In New York with Fred Plum from 1969 to 1970, he carried out experiments on the anaesthetised cat to determine the trajectory of descending bulbospinal pathways responsible-firstly, for the 'central respiratory drive' to respiratory motoneurones in the spinal cord, and secondly, for those responsible for the cough reflex (6). Both questions had their origin in work done at Queen Square, namely that of Peter Nathan on the pathways in man, as deduced from the effects of cervical tractotomy for the relief of intractable pain; and our studies on the effects of selective lesioning and stimulation experiments in the medulla. The experiments were meticulous and with excellent histological control to allow clear conclusions concerning the innervations of the diaphragm and abdominal muscles. Those responsible for the cough lay in the ventral quadrant of the cervical spinal cord, whereas those carrying the respiratory drive were in a ventrolateral location, just as Nathan had found for man (6). These studies epitomised John's interest in seeking experimentally to discover mechanistic explanations to illuminate his clinical work.
John's links with the emerging Department of Neurophysiology continued while he was Physician-in-Charge of the Batten Unit. He collaborated with the Lecturer in Bioengineering in that Department, David Stagg, who developed a comprehensive computer-based analysis of airflow and tidal volume in eupnoea to reveal a complex breath-by-breath variation in such individual parameters as inspiratory and expiratory durations, cycle time, and their correlation with tidal volume (8). Nevertheless, this seemingly random variability was such that mean inspiratory flow rate was held constant, the work providing a fresh insight concerning the homeostatic regulation of breathing. Mike Goldman, an expert on the use of 'magnetometers' for measuring body wall displacements, then at the Harvard School of Public Health, was encouraged to come to Queen Square. This led to a further collaboration in which John, David Stagg and Mike Goldman were able to show that magnetometers placed over the ribcage and abdomen to measure changes in their anterior/posterior diameters provided signals that, coupled to a calibration procedure, allowed the assessment of respiratory function without the need for face masks, a valuable method for sick patients. (9, 11) JND did not entirely neglect this promising early work. Over the next ten years or so, many clinical studies on patients with compromised ventilation were undertaken, mainly with anaesthetist Laurie Loh, who subsequently moved with JND to 14, 20, 21) .
First interests in myasthenia
It was the intercostal muscle preparation that, in 1973, while Physician-in-Charge of the Batten (Intensive Care) Unit, changed the direction of JND's career. As mentioned above, Tom Sears had been contacted by Ricardo Miledi, an electrophysiologist of great distinction who had spent most of the preceding 20 years with Bernard (later Sir Bernard) Katz (FRS 1952; Nobel Laureate 1969) , in the Biophysics Department at University College London. Together they had described and continued to describe many aspects of the physiology of neuromuscular transmission in species from squid to man, including seminal work on the role of calcium in acetylcholine (ACh) release. At the time that JND first got to know them they had just published the first observations on the electrical 'noise' that resulted from application of acetylcholine, providing data that could be used to calculate the behaviour of single ACh receptor (AChR) ion channels (Katz and Miledi 1970) , leading only three years later to the demonstration of single ACh-induced ion channels by their previous visiting fellow, Bert Sachmann, with Edwin Nehers (Nobel Laureate 1991).
Ricardo was medically trained and had followed the work of Elmqvist et al. (1964) showing reduced amplitude of the miniature endplate potentials (MEPPs) in muscles from patients with MG, a disease that had been thought to affect neuromuscular transmission since Jolly's first electromyographic description (Jolly 1895). Those observations helped to understand the neuromuscular weakness but did not resolve the question as to whether the defect was presynaptic-due to reduced release of ACh-or postsynaptic, potentially due to defects in the AChR itself. In fact, at that time the existence of protein 'receptors' for ACh was only just being demonstrated. Ricardo had recently used the snake toxin alpha-bungarotoxin, originally discovered by Chang and Lee (1963) in Taiwan, to quantify and purify AChRs from Torpedo electric organs. It seemed likely that bungarotoxin could be used to analyse AChRs at MG endplates-but he needed to find someone who could provide human muscle biopsies. JND, as part of his work in the Batten Unit, frequently had thymectomized MG patients under his care and, with an introduction from Tom Sears, a highly successful collaboration was quickly established. Intercostal muscle samples were obtained at thymectomy with minimal risk to the patients. Control muscle samples were available from the London Chest Hospital, mainly from patients undergoing thoracotomies for cancer, through the help of chest surgeon Mr Marvin Sturridge who also did the thymectomies at Queen Square.
Within a few weeks, the first muscle biopsies began to arrive at University College London; endplate recordings were made by visiting postdoc Yoshi Ito who confirmed that alpha-bungarotoxin inhibited human muscle neuromuscular transmission and that the MEPPs were indeed substantially reduced in amplitude at MG endplates. The remaining muscle was immersed in radioactive 125 I-alpha-bungarotoxin and the muscle fibre bundles dissected into small sections containing the endplates. Counting these for radioactivity showed that the numbers of 125 I-alpha-bungarotoxin-binding sites, and thus the AChRs, were substantially reduced, confirmed visually by autoradiography of the fixed muscle fibres. Unluckily, Fambrough, Drachman, and Satyamurti published their very similar results in Science in 1973. Having been thoroughly scooped, JND and Ricardo concentrated on making their study more detailed and comprehensive, and it was published in Brain in 1978 (15) .
Meanwhile, a visiting postdoc, Peter Molenaar, had shown that ACh was increased in MG muscle and in rats treated with alpha-bungarotoxin or immunized against AChRs (22) . These observations implied that, in the presence of reduced AChR function, there might be compensatory increases in ACh synthesis and release-findings that were later confirmed when Peter showed an increase in choline acetyl transferase, the enzyme responsible for ACh synthesis (26), and subsequently investigated in more detail in both MG and immunized rats (Plomp et al. 1994 (Plomp et al. , 1995 . This phenomenon of presynaptic compensation in the presence of postsynaptic loss of AChR function is still not fully understood, but has been confirmed in many other laboratories.
Plasma exchange and treatments for myasthenia gravis
During the mid-1970s JND continued to work on intercostal muscle spindles, including describing the endplate morphology in myotonic dystrophy (16, 17) . The move to concentrate on MG followed the exciting developments in the USA where antibodies to AChRs were first identified both in animals immunized against purified receptors (Patrick and Lindstrom 1973) , and then in patients with MG (Lindstrom et al. 1976) , and the demonstration that injection of IgG purified from MG patients reduced MEPPs and AChR numbers, and caused evident weakness, in mice (Toyka et al. 1975) . Extrapolating from the use of plasma exchange in patients with Goodpasture's syndrome, Dr Tony Pinching and Keith (later Sir Keith) Peters (FRS 1995) tried the treatment on two patients with acquired MG and one with congenital myasthenia (13); John subsequently added a hyphen to Newsom in order to ensure that both surnames were used). The rapid (within one to two days) and impressive temporary improvement obtained by simply removing a large proportion of circulating plasma proteins was probably what convinced JND to move from respiratory neurophysiology and concentrate on MG. He obtained a project grant from the MRC, was joined by Angela Vincent who had been doing the alpha-bungarotoxin work in Ricardo's lab, and set up the research group at the RFH with much support and enthusiasm from Peter Thomas.
Myasthenia at the Royal Free Hospital
JND's achievements ultimately involved all of the diseases of the neuromuscular junction. In the passages that follow, most of which represent many overlapping years of work performed by many able scientists and clinicians, including a number of visiting fellows from around the world, JND inspired enthusiasm and commitment while allowing the leaders of the individual subgroups a good deal of independence.
The questions were obvious. How much did the antibodies fall after plasma exchange, and did their levels correlate with clinical indices of disease? The results in six patients showed a remarkable inverse correlation between antibody levels and clinical strength-not only as the AChR antibodies fell during the exchanges, but also as they rose subsequently (18). At this time the main non-interventional treatment was steroids, which could lead to dangerous sideeffects, for example, osteoporosis, diabetes, hypertension. An additional immunosuppressant was azathioprine, following the pioneering work by Mertens et al. (1969) , which seemed to be useful but much slower to act. Some years later JND and ex-clinical fellow Jackie Palace performed the seminal trial of prednisolone alone versus prednisolone plus azathioprine (80), demonstrating that azathioprine reduced the maintenance dose of prednisolone required to achieve clinical remission but, importantly, this effect took ten months to be evident. Not only has the combination of azathioprine and prednisolone become the main first-line immunosuppression in MG and other immune-mediated disorders but the trial approach has been widely adopted and was used in the recent thymectomy trial (see below).
The thymus and antibody synthesis
One of the first projects JND became enthusiastic about was the study of the thymus for which he joined forces with Glenis Scadding, a clinical fellow working with Professor Howard Thomas, at that time in Dame Sheila Sherlock's renowned hepatology department. Glenis was culturing thymic tissue explants in order to see whether the AChR antibodies were produced within the hyperplastic organ. A preliminary report appeared while Glenis was on maternity leave (19), but she subsequently wrote a full report (25) . The production of antibodies by the thymus-only seen in those patients with a 'hyperplastic' thymus-was an exciting, although at first controversial, finding. When presented with the early data, leading immunologist Avrion Mitchison (FRS 1967) walked out of the room muttering something about 'the thymus doesn't contain B cells and doesn't produce antibodies'! Nevertheless, it prompted recruitment of Nick Willcox, a medically qualified immunologist, allowing many future studies on the thymus, the T, B and plasma cells (see below), but also on the effects of thymectomy.
HLA and disease diversity
One of JND's most cited MG papers resulted from his collaboration with (David) Alastair Compston, at that time a neurology trainee at Queen Square, with his PhD supervisor Richard Batchelor. Richard had been involved with the early blood grouping and tissue typing studies at East Grinstead, and recognized their value in demonstrating genetic associations with autoimmune diseases. Alastair was working principally on multiple sclerosis but enthusiastically undertook to analyse the DNA from myasthenia patients, looking, as one had to in those days, for evidence of HLA type by serological cross-matching of fractionated T and B lymphocytes. The results confirmed the high incidence of the HLA B8-DR3 haplotype in myasthenia; but it was restricted to younger patients, whereas HLA B7-DR2 was more frequent if onset of MG was after age 40 years (24) . Thymoma cases, considered separately for the first time, did not show a specific HLA association. This study has not only stood the test of time but clearly indicates the importance of age and pathology stratification of patients when analysing their genetic associations-even when the final disease mechanisms-AChR antibodies in this case-are the same.
Antibody characterization
From 1977 AChR antibodies were provided as a routine diagnostic test by the RFH department (any profits going into a research fund), although the first full study of the antibodies in patients (n = 2,967) was not published until 1985 (37) . Over many years, detailed characterization of the antibodies was achieved, highlighting the great heterogeneity in affinity, subclass, light chain isotype, cross-species reactivity, competition with monoclonal antibodies (mAbs; see below) and particularly an antigenic difference between adult and fetal AChRs and even between the two bungarotoxin-/ACh-binding sites (31, 38, 44, 45) .
By 1979, JND had recruited a new postdoc, Bethan Lang (from Eric Barnard's (FRS 1981) lab at Imperial College). The next recruit was Paul Whiting, JND's and Angela Vincent's first PhD student; this was very fortunate as Paul was an exceptionally modest but effective young man who later worked with Jon Lindstrom at the Salk Institute, returned to the pharmaceutical industry in the UK, became Executive Director and Site Lead of Pfizer's Regenerative Medicine Research Unit, and is currently Chief Scientific Officer of The Alzheimer's Research UK UCL Drug Discovery Institute. Paul purified human AChRs from amputated limbs-a gruesome business that often meant travelling around London on the Underground or buses carrying large heavy bundles wrapped in black plastic bags. He used the purified AChR to immunize mice, created more than ten monoclonal antibodies from their immortalized B cells, and used these to characterize the human AChRs. Not unexpectedly, Paul's monoclonal antibodies proved to be highly specific for different regions on human AChR isoforms, more so than those raised against fish electric organ AChR (Tzartos et al. 1981) . In particular, four mAbs bound only to AChRs from extrajunctional/fetal type muscle and not from the adult neuromuscular junctions (44), foreshadowing the cloning of gamma-and epsilon-subunit genes in 1985 (Shibahara et al. 1985) , which confirmed the molecular distinction previously implied (see above).
The mAbs were also used to characterize, by competition, the antibodies in sera and thymic cultures from patients (39, 45, 52) , confirming that the thymus was indeed a likely source of the full repertoire of antibodies. Some years later, a young clinical fellow, Jeremy Farrar (FRS 2015) (subsequently Director of the Oxford University Clinical Research Unit in Ho Chi Mingh City, Vietnam, and currently Director of the Wellcome Trust), was able to recombine the heavy and light chain genes from mRNA expressed in the thymus of one MG patient and demonstrate that they were highly mutated from diverse immunoglobulin gene origins (77), indicating their polyclonal origin.
Disease mechanisms
Much had been learnt about disease mechanisms in the 1970s from the labs of Andrew Engel, Jon Lindstrom, Dan Drachman, Zach Hall and many others in the USA. These had shown that the antibody binding to the AChRs rarely caused functional inhibition but induced complement-dependent damage to the postsynaptic membrane with loss of the AChRs. They also reduced the surface expression of AChRs on cultured cell lines by a process known as antigenic modulation (binding of divalent antibodies to two adjacent AChRs via one of the paired alpha subunits, which results in their internalization and degradation). The question remained as to whether antigenic modulation really operated in vivo where the natural turnover of AChRs is much slower (half-life 10 days) than on cultured cells. By injecting radioactive alpha-bungarotoxin into pleural cavities of mice that had been injected systemically with MG antibodies, the diaphragm muscle AChRs were labelled and their turnover shown to be increased with a shortened half-life of about four days. However, unexpectedly the synthesis rate of new AChRs also increased, which added postsynaptic compensatory changes to the presynaptic changes mentioned above. These were novel and relevant findings at the time but, having been turned down by Nature, they were published less prestigiously (33, 35) . By 1986 , genetic forms of myasthenia were beginning to be studied and it was clear to JND that this would be a fruitful area for the future. He recruited David Beeson who, like Bethan Lang, had done his PhD with Eric Barnard at Imperial College. The first torpedo and electric (fish) eel AChR subunits had been cloned in Eric's laboratory, in Japan, and in the USA, and David had already described chicken AChR gene sequences and expression during his PhD; but JND wanted the human sequences not only to study the patients with congenital genetic forms of myasthenic syndrome but also to produce human AChR polypeptides and peptides to perform T-cell studies (see below).
Cloning the AChR genes and different human AChR isoforms
It is hard to appreciate how difficult and time-consuming it was in those days with no kits, and techniques that had to be composed more or less from scratch. The first human subunit to emerge from David's work was the beta (55) and then he discovered a novel exon of the human alpha subunit that was generated by alternative splicing and did not appear to be present in other species, apart from close primates. This encoded an extra 25 amino acids and the two isoforms could be distinguished by means of antibodies to the additional 25 amino acids, raised in rabbits (60). The two isoforms appeared to be equally expressed in different human muscles (64) and in the thymus. However, regrettably the expression of the isoform with the additional 25 amino acids (called AChR alpha P3a) did not result in a functional AChR when the cDNAs were injected into Xenopus laevis oocytes (69), and to date no role for this quirk of human genetics has been found either at the normal or myasthenia neuromuscular junction.
Meanwhile David had also produced the first primary cDNA sequences for the gamma and epsilon subunits of the human AChR, which clearly defined the fetal and adult AChRs respectively (65), and chromosomal localizations for the human alpha, beta, delta and epsilon subunits (56). This, and the growing expertise in RNA as well as DNA technologies, enabled a clinical fellow Cal MacLennan to study the expression of the fetal-and adult-defining subunits in human extraocular muscles (75), showing that these muscles expressed a high concentration of RNA for the adult-specific epsilon subunit; this led to confirmation that adult AChR was an important target for antibodies in patients with purely ocular MG (75).
Use of the fetal and adult isoforms, and their expression in Xenopus laevis oocytes (a technique for studying membrane proteins, pioneered by Ricardo Miledi), enabled the group to investigate a rare but devastating condition. A few mothers with MG had been reported to have had babies born with arthrogryposis multiplex congenita (AMC)-multiple joint contractures-often with other deformities. This condition results from lack of intrauterine fetal movement of any cause. JND, with consultant neurologists and geneticists in Oxford, diagnosed MG in a mother with four consecutive affected babies, three of whom had died perinatally from a particularly severe form of AMC (70); moreover, they identified another woman with no history of MG but with a very similar history of five severely affected pregnancies (72). This suggested that AChR antibodies were crossing the placenta, as is normal for all IgG antibodies, and paralysing the fetus during development.
Expanding the immunology-animal models, thymus, germinal centres, and myoid cells
The thymus and antibody formation The finding of antibody synthesis in 1978 by the thymus was exciting. Fortunately, JND was able to convince the scholarly and talented (albeit somewhat eccentric) immunologist Nick Willcox to abandon a tenured non-clinical lecturer appointment in Newcastle in 1979 and join the team at the RFH, supported by JND's newly awarded MRC Programme grant. Nick set about investigating the cells that were involved in the thymus and began to explore antigen-specific T cells and animal models. One surprise was that antibodies against human or mouse AChRs could be induced in mice by injecting mouse AChR-expressing membranes intrathymically or intraperitoneally without the usual adjuvant. The mice frequently became very weak and the AChR antibodies were similar in their specificities to those found in humans with MG (Jermy et al. 1993) .
Nick concentrated mainly on the immunohistology of the thymus, showing that both CD4 lymphocytes and antigen-presenting cells were present in the thymic medulla within the germinal centres (32, 40) . One possibility was that these germinal centres developed in response to viral infection of the thymus, but no evidence for infection could be found (41, 42). However, it had been suggested that AChR was present in the rare cells within the medulla of the thymus that were called thymic myoid cells, and this was confirmed using Whiting's AChR mAbs to stain the thymus (48). Despite their rarity, the myoid cells were often close to the germinal centres, suggesting a role in development of the centres and autoantibody diversification. In fact the thymic B cells cloned were highly mutated as mentioned above (Shiono et al. 2003a ) (91) .
The question remained as to what really initiated these changes. In the 1990s, several groups detected expression of isolated AChR subunits (but not the whole protein) in thymic epithelial cells from MG patients (Wakkach et al. 1996) (92) . Years later, as a result of a collaboration between David Beeson, Henri-Jean Garchon (Paris) and Bruno Kyewski (Heidelberg), a predisposing polymorphism of the AChR alpha subunit gene was found to influence AChR expression in the thymic epithelial cells, particularly under the influence of a protein called the Autoimmune Regulator (AIRE; Giraud et al. 2007 ).
Thymoma
Collaborating with Professor Mary Ritter (Royal Postgraduate Medical School), JND and Nick also scrutinized MG-associated thymomas. These combine neoplastic cortical and medullary epithelial cells with large numbers of maturing T cells (47), many of which are exported to the periphery (84). How the thymoma induces AChR antibodies was hotly debated but, despite claims from others, neither expression of whole AChR nor spontaneous synthesis of AChR antibodies was detected in thymoma tissue (Shiono et al. 2003a,b) , although the adult form of the AChR (containing epsilon subunit) was expressed, and occasional AChR-specific T cells could be cloned from MG thymomas (79).
Acetylcholine receptor-specific T cells
The production of AChR antibodies in the MG thymus, and their correlation with thymic histology (25) , suggested a T-cell-dependent B-cell response to locally expressed AChR (27). To study this, purified AChRs were first obtained from the electric organs of the fish Torpedo but AChR-reactive T cells appeared to be present in both patients and controls (61), and did not distinguish between thymic pathologies (57).
With the cloning of the human AChR subunit genes by David Beeson, and the growing use of synthetic peptides, it became possible to refine the work. Visiting neurologist Ben Ong (subsequently, Chief Executive of the National University Health System and Senior Vice President at the National University of Singapore (2008 Singapore ( -2013 , and currently Director of Medical Services, Singapore (2014-2019)) collaborating with Alain Townsend (FRS 1992) and John Bell (FRS 2008) in the Institute of Molecular Medicine (now Weatherall Institute of Molecular Medicine), identified the first convincing human T cell that responded to a very specific peptide epitope but only in the context of HLA-DR4 with its dimorphic 86 Gly↔Val (59) . This was intriguing as DR4 is not the DR3 (which the patient's cells also expressed) strongly associated with early-onset MG. However, the cloned T cells responded to peptides processed and presented by an HLA-DR4-transfected human muscle AChR-expressing cell line, TE671, indicating their potential relevance.
Despite these early successes, the recombinant AChR subunits were made from E. coli and often the T cells that responded were against E. coli contaminants (73) . Shorter peptides were not naturally processed. Only the responses to native AChR, presented by HLA-matched cells, or by mAbs attached to immunomagnetic beads, demonstrated which clones were truly AChR specific (63).
T-cell clones that responded to an epitope, ε201-219, from three of four patients with earlyonset MG (EOMG) (81, 82) were eventually isolated. Overall, however, only eight AChRspecific clones were identified and they were presented to different T-cell receptors, often by 'minor' class II molecules (HLA-DQ, -DP, DR52a) rather than the HLA-DR molecules that associate strongly with MG. The results of these long years of toil strongly suggested that specific T cells in patients with chronic autoimmune diseases are rare, and questioned the ease with which others had identified 'specific' responses to short peptides or intracellular proteins in other diseases.
Nevertheless, the identification of potentially dominant pathogenic epitopes, even if the responding T cells were rare, raised the possibility of a 'magic bullet' approach for selective therapy in MG. The T cells could be substantially inhibited by pretreatment with specific soluble peptide/HLA-DR4 complexes without co-stimulation (prepared by collaborators at Anergen, a US biotech company) and were then induced to undergo apoptosis indicating promise as long-term therapeutics. Unfortunately, following JND's retirement, the MRC support came to an end, and the therapeutic aims were never achieved.
Congenital myasthenic syndromes
One of the striking, but not altogether unexpected, observations made in the 1970s was that patients with myasthenic symptoms from early childhood did not respond to plasma exchange (and did not have AChR antibodies (23)). Meanwhile Andrew Engel at the Mayo Clinic had begun to study patients with inherited, presumed genetic, conditions (Engel et al. 1982) . From the beginning, working initially with Ricardo Miledi at UCL (28), it was clear that the genetic forms of myasthenia would be rare and heterogeneous. Some patients had reduced numbers of AChRs, whereas others had kinetic abnormalities in AChR function. Some had presynaptic abnormalities resulting in reduced ACh release.
The neuromuscular dysfunction was studied on muscle biopsies from the patients until the advent of better genetic screening allowed identification of mutations in candidate genes (e.g. encoding AChR subunits, rapsyn or muscle specific kinase and DOK7, the latter three proteins being essential for clustering the AChRs at the neuromuscular junction). The functional effects of the mutations were first studied using patch and cell recordings from Xenopus laevis oocytes (as first described for AChRs by Ricardo Miledi), or later from HEK 293 cells transfected with the mutant or wild-type genes. There are now more than 30 different gene targets responsible for different forms of congenital myasthenic syndromes (Rodriguez-Cruz et al. 2018 ).
Lambert-Eaton myasthenic syndrome
In the early 1980s JND started to see patients with the Lambert-Eaton myasthenic syndrome (LEMS), which is often associated with small cell lung cancer. First characterized by Eaton and Lambert (1957) , it was associated with a marked decrease in the presynaptic release of the ACh packets (Elmqvist and Lambert 1968; Lambert and Elmqvist 1971) . Indeed JND had begun to treat patients with 4-aminopyridine, a drug that increases release of ACh (29); he later helped to popularize use of the less neurotoxic 3,4-diaminopyridine for both congenital myasthenic syndrome and LEMS.
At that time the cause of LEMS was unknown; paraneoplastic aetiologies were only just beginning to be studied in detail and some thought that cancer-related neurotoxic factors were responsible for reducing transmitter release (Lambert and Lennon 1982) . On a speculative basis, JND plasma-exchanged three patients (30). All three showed clinical improvements that took 15-20 days to be appreciated (vs 3-5 days in MG). The results encouraged him to start using prednisolone and azathioprine, achieving a remarkable improvement in subsequent patients (30).
At that stage the offending factor could have been any circulating substance that was susceptible to immunosuppression. To show that it was an antibody, Bethan Lang was cajoled into injecting 10 mg of purified LEMS patient IgG intraperitoneally into mice every day (including weekends) for 37-77 days! The quantal content of neuromuscular transmission was then studied by Dennis Wray in the RFH Pharmacology Department; it was significantly reduced in all test animals versus controls, with no effect on miniature endplate amplitudes or AChR numbers (30), strongly indicating that the presynaptic defects in patients were IgG-mediated.
Subsequent studies confirmed the role of an IgG but did not initially identify the target antigen, although the voltage-gated calcium channel was the main candidate. In a collaboration between JND and Dr Andrew Engel at the Mayo Clinic, IgG-treated mouse diaphragms were fixed and sent to Minnesota for freeze-fracture and electron microscopy. Engel and a succession of his visiting Japanese clinical fellows demonstrated beautifully the normal clustering of the presynaptic active zone particles that are voltage-gated calcium channels (VGCCs), and that the patient IgG caused their disorganization/disappearance over time, indicating internalization and destruction of the protein-similar to the antigenic modulation shown earlier in MG. The results correlated with the electrophysiological defects seen in Oxford (34, 46, (49) (50) (51) 54) .
By the mid-1980s, the race was on to demonstrate the antibody target. Bethan Lang found that cancer tumour cells expressed VGCCs and that patient IgG antibodies could inhibit calcium flux into these cells (43), but it took the discovery of cone snail neurotoxins by Olivera et al. (1987) to provide the tools needed for distinguishing the different calcium channel subtypes and thus to identify the true target for the LEMS antibodies. In 1995 VGCC antibodies were demonstrated in >85% of LEMS patients using the 125 I-MVIIC conotoxin to label the appropriate (P-type) VGCC that was immunoprecipitated by LEMS patient antibodies (71) (Lennon et al. 1995) .
A seminal review of 50 cases by JND with John O'Neill and Nick Murray (53) had highlighted the autonomic dysfunction that is often evident, but not always appreciated, in these patients. A visiting Nuffield Fellow from Melbourne, Sally Waterman, undertook a detailed study of the different subtypes of calcium channels mediating transmitter release at autonomic postganglionic synapses (Waterman 1996) . When the mice were given LEMS IgG, not only were the P-type channels selectively decreased but other VGCCs were upregulated, implying compensatory mechanisms (76). Some patients had cerebellar defects as well as LEMS. In a collaboration with Eli Lilly, a marked reduction in P-type VGCC currents in cultured cerebellar granular cells was found in the presence of the patient IgG, but again with an increase in the contribution of other VGCCs (78).
Seronegative myasthenia gravis
It was clear from the earliest days that 10-20% of patients with generalized MG did not have detectable serum AChR antibodies by the radioimmunoprecipitation assay, as originally described by Lindstrom et al. (1976) . Nevertheless, symptoms were often rather severe, involving bulbar and respiratory muscles, and the patients responded extremely well to plasma exchange-which JND used in some cases as a 'diagnostic tool' for distinguishing autoimmune from potentially genetic neuromuscular disorders. Passive transfer experiments were performed, injecting patient IgG into mice; the mice showed a defect in neuromuscular transmission but the numbers of AChRs were not reduced. Many experiments were done over subsequent years without clearly demonstrating a target for the antibodies in so-called seronegative MG, and it was not until 2000 that antibodies to muscle-specific kinase, that is responsible for clustering AChRs at the neuromuscular junction, were identified in many of the patients with seronegative MG who had previously responded to plasma exchange (83) .
Acquired neuromyotonia
In the 1990s with experimental work on LEMS beginning to slow down, JND enjoyed a brief sojourn among the gangliosides in collaboration with Professor Hugh Willison in Glasgow and showed that the neuromuscular junction could also be used to study those antibodies (67, 68) leading to much more detailed investigations by Hugh and his collaborators.
JND's main new focus at this time was acquired neuromyotonia. Again it was the combination of occasional tumours (thymomas), other autoimmune associations, that drew JND's attention to a possible autoimmune aetiology (reviewed with Kerry Mills (66)). The first patient he saw with this condition was a retired Greek colonel who responded to plasma exchange with a dramatic reduction in the typical neuromyotonic discharges recorded by Kerry Mills. Further clinical studies were performed and another antibody-mediated disease was proposed.
The lab work followed the now familiar pattern of passive transfer of IgG to mice to demonstrate that there were pathogenic antibodies. Although in-vitro results using neuronal cell lines were not conclusive, everything pointed to involvement of a potassium channel, and an immunoprecipitation assay was established using radioactive dendrotoxin to label detergent extracts of brain voltage-gated potassium channels. JND with Ian Hart (who died prematurely in 2008), Paul Maddison, and Kerry Mills (who moved to a Chair at King's College London) put together an impressive clinical and neurophysiological description of the disease in 67 patients with 'peripheral nerve hyperexcitability' (a more accurate description than 'neuromyotonia') (86). However, it subsequently became clear that the antibodies were actually directed against other proteins that are complexed with the voltage-gated potassium channels in brain tissue (Irani et al. 2010) . Antibodies to these proteins may also be involved in disorders of the central nervous system and have become the focus of much study in Oxford and centres all over the world.
John Newsom-Davis as clinician
Although JND's excitement seemed to stem mostly from laboratory work, he did not neglect clinical studies and he encouraged the work of those young clinicians who were more suited to 'dry' rather than 'wet' research, particularly if they could lead to a better understanding of the diseases that he had helped to define.
In the clinics, his most productive interactions were with the neurophysiologists, using their skills to demonstrate the use of 4-aminopyridine and the response to plasma exchange in the 36) . Then, as mentioned above, with John O'Neill, Nick and JND reviewed in detail the clinical and physiological aspects of 50 cases of LEMS, in an article that remains the most cited and comprehensive account of the disease (53). The effectiveness of treating the patients with intravenous immunoglobulins in a cross-over study (74) was important, demonstrating that the neuromuscular junction disease, LEMS, improved when the small cell cancer was treated (58).
As mentioned earlier, Jackie Palace, while in clinical training, managed to conduct two important studies with JND: the effects of 3,4-diaminopyridine in congenital forms of myasthenia (62) and the key trial of azathioprine as a steroid-sparing agent in MG (80). The heterogeneity of patients with the CMS that David Beeson identified, including patients with Dok-7 mutations, were clinically characterized (90) and useful clinical clues to the diagnoses of AChR and rapsyn deficiencies were documented (88, 89).
The efficacy of thymectomy in MG had been accepted for many years, but never formally tested. After his retirement, JND switched focus to clinical trials in a characteristically effective manner, helping to promote better and more comprehensive reporting of their results (85) and establishing with US colleagues Gil Wolfe, Henry Kaminski, Fred Jaretski, and Gary Cutter, among others, the first blinded randomized clinical trial of thymectomy in MG (87, 93, 94) . The results were unequivocally positive in showing that thymectomy with steroids not only produced a more effective improvement than steroids alone, but also reduced the dosage of steroids needed by the patients, a benefit that persisted during 5 years of follow-up (reported posthumously by Wolfe et al. 2016 Wolfe et al. , 2019 .
Epilogue
The achievements of JND and the scientists and clinicians who worked with him over the 20 years from 1977 to 1998, when he retired, were focused on a small anatomical structure and a relatively rare set of neurological disease, but they had substantial implications for the recognition and treatment of immune-mediated disorders, as recognized by his election to Fellow of the Royal Society in 1991. JND would have been the first to admit that being in the right place, at the right time, and able to attract talented, hard-working and loyal people were all crucial for his success. Having said that, he was clearly happiest when, changed into his cords, he was at his desk or chatting by a lab bench in the Institute of Molecular Medicine. Over that time, he played a key part in both the clinical and research training of more than 30 neurologists, not only from Britain and its Commonwealth but also from Europe and the Far East.
It is (also) impossible to overstate John's contributions to the evolution of medical care and research at Oxford in his role as a top-class clinical scientist and clinical neurologist. With his delightful, ever-youthful personality he was a wonderful colleague and much beloved by his students and all those who worked for him during his remarkable career. (Professor Sir David Weatherall).
On a trip to Romania in August 2007, after visiting MG patients in Bucharest, John Newsom-Davis was involved in a fatal road accident. His sudden death shocked neurologists throughout the world but his legacies-for example, ongoing neuroimmunological and genetic research in Oxford, a generation of neurologists who acknowledge his many contributions to the discipline and to their own careers, the success of the International Thymectomy Trial, and the rooms at the Academy of Medical Sciences that were subsequently refurbished and named in his memory-bear witness to his intellectual abilities and personal qualities.
Nevertheless, even his closest colleagues did not appreciate the full extent of his contributions, both professional and personal until, following his death, the tributes and recollections began to flow in from patients and doctors all over the world.
